autologous lung spheroid stem cell therapy (University of North Carolina/North Carolina State University/NHLBI)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameautologous lung spheroid stem cell therapy (University of North Carolina/North Carolina State University/NHLBI)
Drug Alias Nameautologous LSCs therapy (University of North Carolina/North Carolina State University/NHLBI)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Lung stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina, Greensboro
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of North Carolina, GreensboroNational Heart, Lung And Blood InstituteNorth Carolina State University
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A